Back to All

Precision medicine has different economics at play

19 September, 2023

The following letter from our CEO, Peter Keeling was published today in the Financial Times

Your article “Piggybacking on US pharma will no longer fly” (The world will need to stop piggybacking on US pharma, September 2) might have mentioned the very different economics at play within precision medicine product portfolios. Recently published US portfolio returns suggest precision medicine drugs are about 25 per cent cheaper to develop and deliver greater clinical outcomes, deserving of value- based pricing. This same analysis suggests that while more needs to be done to invest in patient testing to optimise the return on investment for precision treatment, such testing will probably provide pharma with a strong defence in pricing negotiations. Your article is a good overview of some of the pressures on the pharma C-suites but perhaps should have given more consideration to the shift to precision medicine and the role this will play in delivering more of a balanced value outcome for all.

About Diaceutics

At Diaceutics we believe that every patient should get the precision medicine they deserve. We are a data analytics and end-to-end services provider enabled by DXRX - the world’s first Network solution for the development and commercialization of precision medicine diagnostics. 

Diaceutics has worked on every precision medicine brought to market and provides services to 36 of the world’s leading pharmaceutical companies. We have built the world’s largest repository of diagnostic testing data with a growing network of 2500 labs in 51 countries.

Public Relations & Investor Relations advisers

Alma PR
71-73 Carter Lane

Tel: +44 (0)20 3405 0205 or [email protected]

Caroline Forde
Robyn Fisher
Kieran Breheny